News | Spotlight

More from the company

Published: 2014-12-18 08:25:06

WntResearch AB: Recently published pre-clinical data suggest that Wnt-5a can promote cancer progression in oral squamous carcinoma

WntResearch AB hereby announces that Tommy Andersson’s research group at Lund University has published pre-clinical data demonstrating that Wnt-5a signaling can increase migration and invasion of oral squamous cells. Interestingly enough, these effects of Wnt-5a can be inhibited by the antagonistic peptide Box-5. Theses data support a concept where Wnt-5a is likely to promote progression of the disease and that Box-5 is a possible means of interfering with this progression. The work was published on-line in the Journal of Oral Pathology & Medicine on the 2nd of December, 2014.

VD Nils Brünner comments: “The prognosis for patients diagnosed with Oral Squamous Carcinoma is still poor. The identification of novel therapeutic targets and possible new treatment options for the disease are therefore essential. This early pre-clinical work by Professor Tommy Andersson’s research group is an interesting and exciting step in the right direction” For additional information please contact: Nils Brünner, VD E-mail: nbr@wntresearch.com Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.

Läs mer hos Cision
Read more about WntResearch AB